Circulating tumour DNA (ctDNA) to guide adjuvant chemotherapy and surveillance strategies in patients with stage II colon cancer

这项研究试图证明，基于ctDNA结果的辅助治疗策略将减少接受辅助化疗的II期结肠癌患者的数量，而不会影响无复发生存率。前瞻性多中心研究，入组450例II期结肠癌患者。患者将按照ctDNA结果（A组，n = 300）或标准临床标准（B组，n = 150）以2：1的比例随机分配接受治疗。

This study is attempting to demonstrate that an adjuvant therapy strategy based on ctDNA results will reduce the number of patients with stage II colon cancer receiving adjuvant chemotherapy without compromising recurrence free survival. Prospective multi-centre study enrolling 450 stage II colon cancer patients. Patients will be randomized 2:1 to be treated according to ctDNA results (Arm A, n = 300), or per standard clinical criteria (Arm B, n = 150).